PTK2 and breast carcinoma: For instance, circRPAP2 can bind to the oncogenic splicing factor SRSF1 to compete with the binding between SRSF1 and PTK2 pre-mRNA, thereby attenuating SRSF1-mediated alternate splicing of PTK2 and reduce its expression in breast cancer [184].